Menopause, anti-Müllerian hormone and cognition in a cohort of women with persistent symptoms following TBI: a case for future research. (3rd July 2021)

• Record Type: Journal Article
• Authors: Biscardi, Melissa; Shafi, Reema; Cullen, Nora; Einstein, Gillian; Colantonio, Angela
• Is Part Of: Brain injury. Volume 35:Number 8(2021)
• Page Start: 934
• Page End: 942
• Publication Date: 2021-07-03
• Subjects: TBI -- hormones -- menopause -- cognition -- distress -- long-term outcomes; Brain damage -- Periodicals; Brain -- Wounds and injuries -- Periodicals; Brain Injuries -- Periodicals; 617.481
• DOI: 10.1080/02699052.2021.1929487
• Languages: English
• ISSNs: 0269-9052

Abstract

ABSTRACT: Objectives : Primary: To explore anti-Müllerian Hormone (AMH) levels in community dwelling women following TBI. Secondary: To explore the relation of AMH to menstrual cycle, cognition, distress and symptoms of menopause. Setting: Large adult TBI outpatient clinic in Toronto Canada. Research design: Prospective study of 10 women with persistent symptoms who were one or more years post TBI. Methods: Consenting participants provided a serum sample for AMH levels, and completed the Menopause Rating Scale (MRS), Symptom Checklist-90 r (SCL-90 r), Repeatable Battery for the Assessment of Neurological Status (RBANS) and a health questionnaire. Main outcomes and results: This study found lower than expected levels of AMH in 50% of participants relative to age matched norms and 50% of participants experienced new onset of menstrual changes. Also notable were findings of lower-than-expected cognitive scores in women over 35 and reports of menopause-related symptoms across all ages groups. Conclusions: As our understanding of the role of AMH grows, examining changes in this novel biomarker in the long-term post-TBI is warranted. Future research should be sufficiently powered to expand on and validate the study's findings.